JO3183B1 - طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 - Google Patents

طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Info

Publication number
JO3183B1
JO3183B1 JOP/2011/0021A JOP20110021A JO3183B1 JO 3183 B1 JO3183 B1 JO 3183B1 JO P20110021 A JOP20110021 A JO P20110021A JO 3183 B1 JO3183 B1 JO 3183B1
Authority
JO
Jordan
Prior art keywords
dii4
methods
diseases
disorders
disease
Prior art date
Application number
JOP/2011/0021A
Other languages
English (en)
Inventor
Skokos Dimitris
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of JO3183B1 publication Critical patent/JO3183B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يوفر الاختراع الحالي أساليب لعلاج مرض أو اضطراب، تكون فيه الزيادة في عدد خلايا (تريغ) T التنظيمية مفيدا، عن طريق إعطاء جرعة دوائية لمستهدف يعاني من ذلك المرض أو الاضطراب بجرعة علاجية من ضاد DII4 التي تقيد مسارات إشارة ثلمة-DII4، بذلك يزداد عدد خلايا تريغ. تشمل الأمراض أو الاضطرابات القابلة للعلاج عن طريق أساليب من هذا الاختراع مثل التصلب المتعدد (MS)، داء السكري، وما شابهها. يشمل الضاد المناسب DII4 لهذا الاختراع الأجسام المضادة أو جزيئات من الأجسام المضادة التي تربط بشكل خاص DII4 وتقيد تفاعلات ثلمة-DII4، والمجال الخارجي من DII4، وما شابهها. يوفر الاختراع أيضا أساليب لمنع حدوث أو عودة حدوث هكذا أمراض أو اضطرابات في مستهدف تعرض سابقا أو لديه قابلية للتعرض أو تطوير هكذا أمراض أو اضطرابات. علاوة على ذلك، فإن الأساليب من هذا الاختراع تكون مفيدة لمنع أو لعلاج رفض زراعة الأعضاء أو داء الطعم حيال الثوى.
JOP/2011/0021A 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4 JO3183B1 (ar)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29980110P 2010-01-29 2010-01-29
US36168710P 2010-07-06 2010-07-06
US38869710P 2010-10-01 2010-10-01

Publications (1)

Publication Number Publication Date
JO3183B1 true JO3183B1 (ar) 2018-03-08

Family

ID=43925413

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2011/0021A JO3183B1 (ar) 2010-01-29 2011-01-23 طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2017/0065A JO3242B1 (ar) 2010-01-29 2017-03-19 طرق علاج داء السكري بمستضادات dll4

Country Status (29)

Country Link
US (3) US8889133B2 (ar)
EP (2) EP2528946B1 (ar)
JP (2) JP5883801B2 (ar)
KR (2) KR101832118B1 (ar)
CN (2) CN102947336B (ar)
AR (1) AR080026A1 (ar)
AU (2) AU2011210771B2 (ar)
BR (2) BR112012018820A8 (ar)
CA (2) CA2787394C (ar)
CY (2) CY1118223T1 (ar)
DK (2) DK2528946T3 (ar)
ES (2) ES2609663T3 (ar)
HR (2) HRP20170130T1 (ar)
HU (2) HUE032985T2 (ar)
IL (2) IL220889A (ar)
JO (2) JO3183B1 (ar)
LT (2) LT2528946T (ar)
MX (2) MX343553B (ar)
MY (2) MY156538A (ar)
PL (2) PL2528946T3 (ar)
PT (2) PT2528945T (ar)
RS (2) RS55595B1 (ar)
RU (2) RU2587620C2 (ar)
SG (4) SG182527A1 (ar)
SI (2) SI2528945T1 (ar)
SM (3) SMT201600412B (ar)
TW (2) TWI564019B (ar)
UY (1) UY33206A (ar)
WO (2) WO2011094465A1 (ar)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BR112012004546A8 (pt) 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
HUE029661T2 (en) 2009-10-16 2017-03-28 Oncomed Pharm Inc A therapeutic combination and use of DLL4 antagonist antibodies and antihypertensive agents
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
KR101853278B1 (ko) 2010-03-02 2018-05-02 애브비 인코포레이티드 치료학적 ｄｌｌ４ 결합 단백질
LT3485903T (lt) 2011-09-23 2023-02-27 Mereo Biopharma 5, Inc. Vegf/ dll4 surišantys agentai ir jų panaudojimas
KR101535341B1 (ko) * 2012-07-02 2015-07-13 한화케미칼 주식회사 Dll4에 특이적으로 결합하는 신규한 단일클론항체 및 이의 용도
TW202037609A (zh) 2012-11-01 2020-10-16 美商艾伯維有限公司 抗-vegf/dll4雙重可變區域免疫球蛋白及其用途
AR093445A1 (es) * 2012-11-14 2015-06-10 Regeneron Pharma Metodos para tratar el cancer de ovario con antagonistas de dll4
ES2742855T3 (es) 2013-07-09 2020-02-17 Ablbio Nueva proteína de objetivo doble que se une específicamente a DLL4 y CEGF, y uso de la misma
CN111879948A (zh) * 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
PL3129483T3 (pl) * 2014-04-08 2019-05-31 Fraunhofer Ges Forschung Terapia skojarzona do leczenia chorób autoimmunologicznych
ES2808153T3 (es) 2014-10-31 2021-02-25 Mereo Biopharma 5 Inc Terapia de combinación para tratamiento de enfermedad
US11339213B2 (en) 2015-09-23 2022-05-24 Mereo Biopharma 5, Inc. Methods and compositions for treatment of cancer
WO2020113099A1 (en) * 2018-11-29 2020-06-04 Gary Aaron Howard Method for treating or preventing seizures associated with an epileptic disorder
US11446262B2 (en) 2018-11-29 2022-09-20 Debora Zucco Sassi Yonezawa Siviglia Neuroquiescence—a treatment for neurodevelopmental and neurodegenerative bioelectrical dysregulation and demyelination
US20240287173A1 (en) * 2021-03-30 2024-08-29 National University Corporation Kumamoto University Therapeutic agent for muscular atrophy
US20250163146A1 (en) * 2022-02-18 2025-05-22 H. Lee Moffitt Cancer Center And Research Institute, Inc. Single-domain antibodies (nanobodies) targeting the notch ligand dll4 and methods of their use
WO2025212726A2 (en) 2024-04-04 2025-10-09 Compass Therapeutics, Inc. Combination of antibodies targeting dll4/vegf and cd137 agonists or anti-pd1/anti-pd-l1 antibodies for the treatment of cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US20060134121A1 (en) 2004-10-29 2006-06-22 Gavin Thurston DII4 antagonists, assays, and therapeutic methods thereof
CA2630839C (en) 2005-12-16 2017-01-17 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with dll4 antagonists
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
EP2029159A2 (en) 2006-06-06 2009-03-04 Genentech, Inc. Compositions and methods for modulating vascular development
NZ572177A (en) * 2006-06-06 2012-02-24 Genentech Inc Anti-dll4 antibodies and methods using same
HRP20130271T1 (hr) * 2006-08-07 2013-04-30 Regeneron Pharmaceuticals, Inc. Upotreba dii4 antagonista kod ishemijskih ozljeda ili vaskularne insuficijencije
DK2066694T3 (en) 2006-09-29 2016-02-08 Oncomed Pharm Inc Compositions and Methods for Diagnosing and Treating Cancer
RU2448979C2 (ru) 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
BR112012004546A8 (pt) 2009-08-29 2017-12-05 Abbott Lab Terapêutica por proteínas ligantes dll4-ligantes
JO3183B1 (ar) * 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4

Also Published As

Publication number Publication date
WO2011094467A3 (en) 2011-12-22
SG10201500404QA (en) 2015-03-30
RS55595B1 (sr) 2017-06-30
MX2012008638A (es) 2012-12-05
IL220889A (en) 2017-07-31
MX2012008740A (es) 2012-08-31
MY156353A (en) 2016-02-15
KR101832118B1 (ko) 2018-02-26
TWI600433B (zh) 2017-10-01
TW201136601A (en) 2011-11-01
CA2787394A1 (en) 2011-08-04
CA2787394C (en) 2019-01-08
CA2787615A1 (en) 2011-08-04
HRP20170249T1 (hr) 2017-04-07
AU2011210773B2 (en) 2015-11-19
BR112012018820A2 (pt) 2017-01-10
CY1118223T1 (el) 2017-06-28
JP2013518122A (ja) 2013-05-20
RU2587624C2 (ru) 2016-06-20
CY1118551T1 (el) 2017-07-12
KR20130008017A (ko) 2013-01-21
UY33206A (es) 2011-08-31
RU2012136816A (ru) 2014-03-10
US20110189200A1 (en) 2011-08-04
US8765125B2 (en) 2014-07-01
SG10201500416RA (en) 2015-04-29
MY156538A (en) 2016-02-26
US8889133B2 (en) 2014-11-18
KR101797918B1 (ko) 2017-11-15
SI2528946T1 (sl) 2017-01-31
WO2011094465A1 (en) 2011-08-04
RS55715B1 (sr) 2017-07-31
BR112012018766A2 (pt) 2017-01-10
IL220889A0 (en) 2012-09-24
HRP20170130T1 (hr) 2017-03-24
EP2528945B1 (en) 2016-10-26
DK2528946T3 (en) 2017-02-20
KR20120123745A (ko) 2012-11-09
RU2587620C2 (ru) 2016-06-20
PT2528945T (pt) 2016-12-14
JO3242B1 (ar) 2018-03-08
PL2528945T3 (pl) 2017-02-28
TW201615207A (zh) 2016-05-01
LT2528945T (lt) 2017-01-25
PL2528946T3 (pl) 2017-04-28
CN102884081A (zh) 2013-01-16
WO2011094467A2 (en) 2011-08-04
US20110189176A1 (en) 2011-08-04
MX343555B (es) 2016-11-10
JP5883801B2 (ja) 2016-03-15
EP2528946A1 (en) 2012-12-05
US20140255429A1 (en) 2014-09-11
HUE031432T2 (en) 2017-07-28
AR080026A1 (es) 2012-03-07
JP5997613B2 (ja) 2016-09-28
IL220887A (en) 2017-07-31
PT2528946T (pt) 2016-12-14
CA2787615C (en) 2019-01-15
DK2528945T3 (en) 2017-02-06
AU2011210771B2 (en) 2015-12-10
ES2609663T3 (es) 2017-04-21
AU2011210771A1 (en) 2012-08-23
AU2011210773A1 (en) 2012-08-23
WO2011094465A4 (en) 2011-09-22
JP2013518123A (ja) 2013-05-20
EP2528945A2 (en) 2012-12-05
SG182527A1 (en) 2012-08-30
SMT201700021T1 (it) 2017-03-08
EP2528946B1 (en) 2016-11-16
LT2528946T (lt) 2017-01-25
SMT201600412B (it) 2017-01-10
BR112012018820A8 (pt) 2018-03-13
ES2605430T3 (es) 2017-03-14
CN102947336A (zh) 2013-02-27
HUE032985T2 (en) 2017-11-28
SI2528945T1 (sl) 2017-01-31
SMT201700021B (it) 2017-03-08
RU2012136817A (ru) 2014-03-10
SG182528A1 (en) 2012-08-30
CN102947336B (zh) 2015-12-02
TWI564019B (zh) 2017-01-01
MX343553B (es) 2016-11-10

Similar Documents

Publication Publication Date Title
JO3183B1 (ar) طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
Jordan et al. A novel targeted approach to the treatment of hemophagocytic lymphohistiocytosis (HLH) with an anti-interferon gamma (IFNγ) monoclonal antibody (mAb), NI-0501: first results from a pilot phase 2 study in children with primary HLH
Sun et al. Macrophage phenotype in liver injury and repair
Walsh et al. Proteasome inhibitor-based therapy for antibody-mediated rejection
AU2017278220B2 (en) Receptor selective retinoid and rexinoid compounds and immune modulators for cancer immunotherapy
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
EA033400B1 (ru) Антитело против cd3 и его применение
EA201290849A1 (ru) Оптимизированные моноклональные антитела против ингибитора пути тканевого фактора (tfpi)
TW200716743A (en) Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MY160892A (en) Antibodies to ccr2
MX348577B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EA201190043A1 (ru) Имидазопиразиновые ингибиторы syk
EA201591191A1 (ru) Антитела против ntb-a и связанные с ними композиции и способы
EA201490279A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
MX2010007406A (es) Anticuerpos anti-factor inhibidor de migracion de macrofago (mif).
EA201100779A1 (ru) Композиции антител к cxcr1 и способы их применения
Cong et al. Blocking two-pore domain potassium channel TREK-1 inhibits the activation of A1-like reactive astrocyte through the NF-κB signaling pathway in a rat model of major depressive disorder
Kukharsky et al. In a search for efficient treatment for amyotrophic lateral sclerosis: Old drugs for new approaches
EA201500506A1 (ru) КОНЪЮГАТЫ И МАЛЫЕ МОЛЕКУЛЫ, ВЗАИМОДЕЙСТВУЮЩИЕ С РЕЦЕПТОРОМ CD16a
RU2014117952A (ru) Антитела против sema4a человека, используемые для лечения заболевания
EA202192488A1 (ru) Антитела против tsg-6 и их применения
DE602006019977D1 (de) Therapie mit anti-cd4-antikörpern und bestrahlung
Wang et al. Cytokine Storm Induction Linked to Multi‐Organ Failure in Fatal Jellyfish Stings
PH12019500482A1 (en) Antibody for treating autoimmune diseases